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Abstract
Goals of work Clinical trials have suggested that advances
in chemotherapy significantly improve the survival of
patients with metastatic colorectal cancer. Comparable
evidence from clinical practice is scarce. This study aims
to investigate the survival of patients with metastatic
colorectal cancer treated with chemotherapy in Alberta,
Canada.
Patients and methods Trends of relative survival of patients
diagnosed in 1994–2003 were assessed using Alberta Cancer
Registry (ACR) data. The median overall survival (OS) of
patients diagnosed in 2004 was determined by linking
Cancer Registry data with Electronic Medical Records
(EMR). Cox regression models were fitted to calculate the
hazard ratio for patients treated with chemotherapy.
Results The 2-year relative survival for patients with
metastatic colorectal cancer who received chemotherapy
increased significantly from 29% to 41% over the 10 years
(1994–2003, p<0.015). A 69% reduction in the risk of
mortality was observed in the 168 patients who received
chemotherapy compared to the 87 patients who did not,
after adjusting for age, gender, and number of metastases.
The median OS of patients who received chemotherapy was
17.5 months. This is comparable to the 18–20 months seen
in recently published clinical trials, considering the patients
in this study were from the real clinical practice, nearly half
of them were older than 70, and many of them might have
important co-morbidities.
Conclusions The survival of patients diagnosed with
metastatic colorectal cancer in Alberta has improved in
recent years; this is most likely attributable in large part to
the use of chemotherapy.
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Introduction
Colorectal cancer is the second leading cause of cancer
death in both Alberta and the Western world [1]. The 5-year
survival rate for colorectal cancer cases in Alberta was
estimated to be 59% (95% confidence interval (CI)=57–
61%); this was similar to the rate for all of Canada, 61%
(95% CI=60–62%) [2]. A continual downward trend in the
colorectal cancer mortality rate was observed between 1994
and 2003 in Canada despite a fairly stable incidence rate
during this same 10-year period. It has been suggested that
this decrease in mortality reflects improvements in treat-
ment, particularly chemotherapy [3]. Screening for colorec-
tal cancer can also reduce both incidence and mortality.
However, screening was not likely responsible for this
observed reduction in colorectal cancer mortality as the
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National Recommendation for Screening for Colorectal
Cancer was first published in 2001 [4] and the estimated
screening rate in Alberta had been low in 2004 [5]. The
apparent impact of chemotherapy on the decreasing
mortality rates of colorectal cancer patients in Alberta
requires a more detailed assessment.
Survival after a diagnosis of colorectal cancer is largely
determined by whether the cancer has spread (metastasized)
and the extent of this spread at the time of diagnosis.
Survival can be predicted by establishing the cancer stage
[6]. A study using Surveillance, Epidemiology, and End
Results (SEER) data for 1973–1997 showed that the 5-year
relative survival rate of colorectal cancer was 5% for stage
IV, 55% for stage III, 87% for stage II, and 96% for stage I
[7]. The results from the analysis of more recent SEER data
(1991–2000) showed that the 5-year stage-specific survival
for colon cancer was 8% for stage IV, 60% for stage III,
83% for stage II, and over 93% for stage I [8]. Patients
diagnosed with stage IV colorectal cancer, in which distant
metastasis has occurred, have the worst outcomes. This
emphasizes the importance of detecting colorectal cancer
earlier, ideally before metastasis occurs. Unfortunately,
approximately half of all patients with colorectal cancer
will develop metastatic disease. Without treatment, the
median OS time is approximately 9 months after the
detection of metastases [9]. Evidence from clinical trials
has shown that the availability of new active chemotherapy
drugs in the treatment of metastatic colorectal cancer
patients has greatly improved the prognosis of these
patients in recent years. Ten years ago, the treatment was
based on one drug only, 5-fluorouracil (5-FU). With the
availability of new active drugs and the development of
new drug combinations, a patient with metastatic colorectal
cancer should be expected to have a median survival of 18–
20 months compared to that of 11–14 months just a few
years ago [10, 11].
Evidence from population-based cancer survival analysis
and reviews of clinical trials suggest that advances in
chemotherapy can improve the survival of colorectal cancer
patients, in particular the OS of those patients with distant
metastases. Previous reports have emphasized the impor-
tance of linking data from population-based cancer regis-
tries and cancer care databases in order to monitor the
quality of cancer treatment [12, 13]. Identification of all
cancer diagnoses from a population-based cancer registry,
followed by an evaluation of the outcomes, provides an
opportunity for the results to be generalized to the total
population. Chemotherapy information has been available
in Electronic Medical Record (EMR) of the Alberta Cancer
Board (ACB) since 2002. Therefore, the linkage between
the population-based Cancer Registry data and EMR data
for studying treatment outcomes has only recently become
possible. The aim of the current study is to investigate the
survival of metastatic colorectal cancer patients treated with
chemotherapy in Alberta and to assess whether there has
been improvement in recent years as was reported in the
literature.
Methods
Patients diagnosed with invasive adenocarcinoma of the
colon, rectosigmoid junction, and rectum between 1994 and
2004 were included in this study. Study cases were selected
from ACR using a combination of ICD-O topography
codes (C18, C19, and C20) and morphology codes for
adenocarcinoma [14]. Cases of other or unspecified
carcinoma, lymphoma, and sarcoma were excluded. Cases
confirmed by cytology or histology were included while
cases whose diagnoses were confirmed only by clinical
examination, radiology, autopsy, or death certificate were
excluded. These comprised around 10% of the overall
colorectal cancer cases diagnosed in the study period.
Patients with multiple primary cancers were not excluded in
order to reflect the patient population. Cases diagnosed with
distant metastases at the time of diagnosis were identified.
Cases diagnosed in 2004 were linked with the EMR in
the ACB's Varis Medical Oncology Manager Database
using the patient's unique identification number. Informa-
tion about patients' age, gender, diagnosis, metastasis,
initial treatment, and last known vital status was extracted
from ACR, whereas the patients' cancer center appointment
and treatment information was obtained from the EMR. The
ACR is a population-based cancer registry that has a proven
high level (over 95%) of completeness for registration of all
new cancer incidences and cancer deaths in Alberta,
according to the standards of the North American Associ-
ation of Central Cancer Registries [15]. The Cancer
Registry conducts active follow-up every month to obtain
the vital status of all cancer patients dying in Alberta
through Alberta Vital Statistics. Every year, the Cancer
Registry also links with the national vital statistics database
to confirm the number of deaths among cancer patients and
to identify the vital status of those patients who moved
from Alberta to other Canadian provinces. In this way,
virtually all patients with metastatic colorectal cancer at
diagnosis in Alberta can be identified. Since all chemother-
apy treatments for metastatic colorectal cancer patients in
Alberta are provided by the cancer treatment centers of the
ACB, patients who received chemotherapy can be identi-
fied from the EMR system of the ACB.
At the current stage of EMR implementation, there is no
single indicator confirming the administration of chemo-
therapy; however, there are several potential indicators
which can be used as surrogates. These include initial
treatment data from the Cancer Registry database, appoint-
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ment information for chemotherapy administration, location
of the treatment appointments in the EMR, drug dosage
recording information, and the name of the chemotherapy
regimen used. Although the latter two indicators can
provide more specific information concerning the chemo-
therapy treatment, they were incomplete at the time of this
review as the on-line ordering of chemotherapy drugs had
not yet been fully implemented. Therefore, in this study, the
location and the date of the first chemotherapy appointment
were used as indicators for chemotherapy administration.
Patients included in this study were tracked through to
September 30, 2006. Two types of survival analysis were
carried out. First, the 10-year trends of relative survival
were assessed using cases diagnosed between 1994 and
2003; a comparison was made between patients who
received chemotherapy as the initial treatment to those
who did not. Relative survival is the ratio of the observed
survival rate in a group of cancer patients to the expected
survival rate for a group of people in the general population
with similar gender, age, residence, and calendar time
period. Age- and sex-specific mortality rates in the general
population were obtained from 1996–2001 life tables
provided by Statistics Canada for Albertans. The 5-year
survival rate has conventionally been used as an index for
comparing survival across groups of patients. However, the
choice of survival interval, such as 1 year, 2 years, or
5 years after the diagnosis, will depend on the prognosis of
the cancer concerned and the number of individuals
(usually requires more than ten patients) entering a survival
interval [16]. In this study, 1-year, 2-year, and 5-year
relative survival rates with 95% confidence intervals (CIs)
were calculated. In order to stabilize the survival rates,
calculations were carried out for cases diagnosed in every
2 years (e.g., diagnosis calendar years 1994–1995 and
2002–2003) rather than in a single year. The relative
survival rates between the years 1994 and 1999 were
computed using cohort analysis whereas the rates between
2000 and 2003 were predicted rates using period analysis
(when complete follow-up data are not available) [17]. The
Ederer-II method was used to estimate the expected
survival rate [18].
Second, a retrospective survival analysis was conducted
by reviewing a cohort of patients diagnosed with metastatic
colorectal cancer in 2004. Median OS time and the 95% CI
of these patients were calculated for two follow-up periods
with two respective starting dates. The first follow-up was
from the first appointment of any treatment to the date of
death or the last follow-up; the second follow-up was from
the date of the first appointment of chemotherapy to the
date of death or the last follow-up. Patients without a death
record at the end of follow-up were assumed to be alive.
Survival curves were estimated using the Kaplan–Meier
method. A log-rank test was performed to determine the
statistically significant differences between the survival
curves. A Cox regression model is fitted to compare the
survival of patients who received chemotherapy compared
to those who did not, accounting for potential confounding
factors associated with treatment and survival outcomes.
These confounding factors included age at diagnosis,
gender, site of metastasis, number of metastasis, and having
multiple primary cancers. All through the analyses, p values
less than 0.05 were considered statistically significant.
Statistical analyses were performed using SAS 9.1 (SAS
Institute Inc, Cary, NC, USA). Ethical approval was
obtained from the Research Ethics Board of the ACB.
Results
Between 1994 and 2003, 11,360 Albertans were diagnosed
with invasive colorectal cancer and were microscopically
confirmed to be adenocarcinoma. Of them, 2,196 (19%)
had distant metastasis at the time of their diagnosis. The
proportion of patients with distant metastases was higher in
younger patients than in older patients, with 27% among
patients in age <50, 24% in 50–59, 21% in 60–69, 18% in
70–79, and 13% in 80+. The average and median age of the
patients with metastatic colorectal cancer was 66 and
67 years, respectively. A patient may receive more than
one treatment (e.g., chemotherapy, surgery, radiation ther-
apy, etc.) according to their initial treatment plan. On
average, about 40% of the patients diagnosed with distant
metastasis in 1994–2003 received chemotherapy in their
initial treatment. This proportion was doubled, from 26% in
1994–1995 to 51% in 2002–2003. Table 1 shows the trends
of relative survival rates for five cohorts (each cohort
contained two calendar years of diagnosis) stratified based
upon presence or absence of distant metastasis and whether
they received chemotherapy or not. A statistically signifi-
cant increase in survival rates is observed for patients who
received chemotherapy but not for the patients in the non-
chemotherapy group. For the patient who had distant
metastasis at the time of diagnosis, and received chemo-
therapy, the 1-year survival rate increased from 63% in
1994–1995 to 75% in 2002–2003 (p=0.016) and the 2-year
survival rate increased from 29% to 41% (p=0.015) in the
same time period. The 5-year survival rate also increased
for this group, but this increase was not statistically
significant (p=0.122).
In 2004, 1,513 Albertans were diagnosed with colorectal
cancer. Among them, 378 (25%) had distant metastasis at
the time of diagnosis and 374 of the 378 had attended any
ACB-affiliated cancer treatment center. The information of
these 374 patients was obtained from the EMR of ACB.
The four remaining cases were elderly patients who died
soon after diagnosis with unknown treatment. In total, 328
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(194 male and 134 female) of the 374 patients were
included in this study according to the case selection
criteria of this study. Furthermore, about half (46%) of this
study group were of age 70 years and older at the time of
diagnosis. The major sites of the metastases were liver
(239), lung (81), peritoneum (77), and non-regional lymph
node (40). For the 328 patients in this review, the median
length of time from date of diagnosis to the date of death or
the last follow-up was 11.9 months, ranging from less than
a month to 33.8 months. At the end of follow-up, 253
(77%) patients had died with 229 (91%) of them dying
from colorectal cancer. The causes of death for the
remaining 24 patients were due to another cancer or
anything not related to cancer; these were censored in the
cause-specific survival analysis.
In total, 255 of the 328 patients had their first
appointment for any treatment in a cancer treatment center
in Alberta. Among 73 patients who did not have treatment
appointments in the cancer treatment centers, 69 had died
within 2 months. The remaining four patients died from
other or unknown causes. When the total 255 patients were
followed from the date of the first appointment of any
treatment to the date of death/last follow-up, the median OS
was 18.2 months for patients aged under 70 compared to
10.2 months for patients over 70 year of age (p<0.0036).
Patients aged under 70 were more likely to receive
chemotherapy than patients aged over 70 (Table 2).
A total of 168 of the 255 patients received chemotherapy.
Results from the multivariate analysis using Cox models have
shown that chemotherapy significantly improved the chance
of survival (HR=0.31, 95% CI=0.21–0.44). The hazard ratio
(HR) of 0.31 represents a 69% reduction in the risk of
mortality. In contrast, being over the age of 70 (HR=1.44,
95%CI=1.00–2.07) or having more than one distant meta-
static sites significantly reduced the chances of survival (HR=
2.27, 95% CI=1.62–3.19) (Table 3). When the 168 patients
treated with chemotherapy were followed from the date of
their first chemotherapy appointment to the date of death/last
follow-up, the median OS was 17.5 months (95% CI=14.3–
21.3) (Fig. 1). Among this group, patients aged over 70 had
a significantly lower chance of survival than patients aged
under 70 years of age (p=0.0031).
Table 1 One-, 2-, and 5-year relative survival rates % and (95% CIs) for patients diagnosed with microscopically verified with adenocarcinoma
colorectal cancer in Alberta, 1994–2003
Survival
interval
1994–1995 1996–1997 1998–1999 2000–2001 2002–2003 p value
Metastatic Overall n 364 345 409 514 564 –
1-year 37 (32, 42) 34 (29, 39) 41 (36, 46) 46 (42, 51) 52 (48, 57) <0.001
2-year 16 (12, 19) 14 (10, 17) 19 (15, 23) 22 (18, 26) 28 (24, 4) <0.001
5-year 6 (3, 8) 4 (2, 6) 4 (2, 6) 7 (4, 10) 10 (6, 13) 0.039
With chemotherapy n 94 110 159 227 289 –
1-year 63 (53, 73) 52 (42, 61) 57 (50, 65) 70 (63, 76) 75 (70, 80) 0.016
2-year 29 (19, 38) 24 (16, 32) 27 (20, 34) 34 (27, 41) 41 (35, 47) 0.015
5-year 10 (4, 17) 7 (2, 13) 7 (3, 11) 13 (6, 19) 16 (9, 22) 0.122
Without chemotherapy n 270 235 250 287 275 –
1-year 28 (22, 33) 25 (20, 31) 31 (25, 37) 29 (23, 34) 29 (23, 34) 0.368
2-year 11 (7, 15) 9 (5, 13) 14 (9, 18) 13 (9, 17) 14 (9, 18) 0.155
5-year 4 (2, 7) 3 (<1, 5) 2 (<1, 5) 3 (1, 6) 4 (1, 7) 0.428
Non-metastatic Overall n 1,567 1,670 1,814 2,005 2,075 –
1-year 91 (89, 92) 90 (88, 92) 90 (88, 91) 90 (89, 92) 93 (91, 94) 0.040
2-year 82 (80, 85) 83 (81 86) 83 (81, 85) 84 (82, 86) 88 (86, 90) <0.001
5-year 71 (68, 74) 71 (68, 74) 70 (67, 73) 71 (68, 73) 77 (74, 79) 0.002
With chemotherapy n 388 444 522 584 644 –
1-year 94 (92, 97) 96 (94, 99) 97 (95, 98) 96 (94, 98) 98 (97, 100) 0.002
2-year 82 (78, 86) 89 (86, 92) 88 (85, 91) 88 (84, 91) 91 (88, 93) <0.001
5-year 63 (58, 69) 71 (66, 76) 71 (67, 76) 69 (64, 73) 76 (72, 80) <0.001
Without chemotherapy n 1,179 1,226 1,292 1,421 1,431 –
1-year 89 (87, 91) 88 (86, 90) 87 (85, 89) 88 (86, 90) 90 (88, 92) 0.373
2-year 82 (80, 85) 81 (79, 84) 81 (78, 84) 82 (80, 85) 87 (84, 89) 0.011
5-year 73 (70, 77) 71 (67, 74) 70 (66, 73) 72 (68, 75) 77 (73, 80) 0.102
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Discussion
The proportion of patients with metastatic colorectal cancer
treated with chemotherapy has doubled in the past 10 years.
Throughout the same period, we have also seen a
significant increase in survival rates for patients who
received chemotherapy, more for 1-year and 2-year survival
than for 5-year survival. In addition to the evaluation of
trends in relative survival over a 10-year period, patients
with metastatic colorectal cancer diagnosed in 2004 were
also reviewed. We saw a 69% reduction in the risk of
mortality in patients who received chemotherapy compared
to those who did not receive chemotherapy. The median OS
of patients who received chemotherapy was 17.5 months.
This was similar to the median OS of 18–20 months, based
on a review of recently published clinical trial studies.
Further investigation is required in order to determine
whether such improvement was due to the increased use of
chemotherapy or advances made in the efficacy of
chemotherapy drugs.
There are several strengths of the present study. Patients
included in this study were identified from a population-
based cancer registry and included almost all patients
diagnosed in Alberta in the past 11 years. Results from
this study should represent the cancer patient population in
Alberta as a whole. Improvements in survival rates over
time have often been used as an indicator for advances
made in cancer treatment. However, survival rates may also
Factors From first treatment appointment to the last follow-up
Chemo/total (%) 168/255 (66%) Median OS (in months) (95% CI) p value
Gender
Male 93/149 (62%) 13.5 (11.2–17.1) 0.398
Female 75/106 (71%) 16.1 (10.5–20.8)
Age
70 years and older 42/91 (46%) 10.2 (6.7–12.9) 0.004
Less than 70 years 126/164 (77%) 18.2 (15.0–22.1)
Number of malignancies
2 or more 37/60 (62%) 12.2 (6.7–19.0) 0.140
1 131/195 (67%) 15.0 (12.8–19.1)
Number of metastases
2 or more 56/89 (63%) 9.2 (5.4–12.0) <0.001
1 112/166 (67%) 19.8 (15.0–26.6)
Metastatic sites
Hepatic 120/181 (66%) 14.3 (10.9–17.7) 0.089
Non-hepatic 48/74 (65%) 15.6 (11.5–32.5)
Table 2 Median overall survival
(OS) for metastatic colorectal
cancer cases diagnosed in
Alberta, 2004
Factors From first treatment appointment to the last follow-up
Case Unadjusted HR Adjusted HR
N=255 (95% CI) (95% CI)
Chemo
Yes 168 (66%) 0.31 (0.22–0.44) 0.31 (0.21–0.44)
No 87 (34%) 1.00 1.00
Age
70 years and older 91 (36%) 1.67 (1.20–2.31) 1.44 (1.00–2.07)
Less than 70 years 164 (64%) 1.00 1.00
Metastases
# Sites
2 or more 89 (35%) 2.03 (1.47–2.81) 2.27 (1.62–3.19)
1 166 (65%) 1.00 1.00
Site
Hepatic 181 (71%) 1.37 (0.96–1.97) 1.33 (0.91–1.94)
Non-hepatic 74 (29%) 1.00 1.00
Table 3 Hazard ratios (HR) of
mortality for patients with
metastatic colorectal cancer in
Alberta, 2004
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improve if cancers are detected at an earlier stage, even if
no progress has been made in cancer treatments. Without
stage-specific survival information, interpretation of the
improved survival observed is limited [8]. The current
study was able to focus on the survival of patients with late-
stage colorectal cancer for which chemotherapy is the main
treatment modality. Observed improvements in the survival
of patients with metastatic colorectal cancer, therefore, were
probably due to chemotherapy treatment. Previous studies
based on large population-based cancer registry data in
Europe and in the USA have shown that the survival of
colorectal cancer varies with morphology type [19]. For
example, Carcinoid had a 5-year relative survival rate of
83% compared to 62% for overall colorectal cancer. In
addition, cases with a microscopically confirmed diagnosis
generally displayed better survival than those which did
not. The 5-year survival rate was only 9% for cases with no
microscopically confirmed diagnoses. In order to monitor
the survival trends accurately, this study has only included
microscopically confirmed adenocarcinoma cases which
comprised 90% of the colorectal cancer cases diagnosed in
the study period.
Although there are strengths of the present study, there
are also limitations. Greater survival rates observed in
patients who received chemotherapy, in part, can be
attributed to the selection of healthier patients into the
treatment group. Although we assessed the association
between chemotherapy and survival using multivariate
analysis to account for the differences in age, gender, and
characteristics of the metastasis between groups of patients
who received and who did not receive chemotherapy, many
factors influencing the chemotherapy decisions and survival
outcomes are difficult to measure and control completely.
These confounding factors may include socio-economic
factors and patients' health status. Patient preferences may
also have impacted the chemotherapy decision, but we were
not able to capture this information from the existing EMR
cancer clinical database. Additional data linkage with the
provincial health administrative database that covers a wide
range of health services activities provided to Albertans
may offer opportunities to collect further information on co-
morbidities of the cancer patients. Due to this limitation, the
study was not able to establish a direct causal relationship
but to suggest an association between the observed survival
improvement of the metastatic colorectal cancer patients
and the chemotherapy treatment that they received.
Only median OS was measured using the existing clinical
database in this study. Other indicators, such as time-to-
progression and progression-free survival, can provide better
outcome information for a specific treatment but they cannot
be measured directly in the present EMR system. This is
because the information on progression/recurrence is only
routinely available from physicians' dictated notes and not
in a format that can be extracted electronically. A manual
review would be required to obtain this information.
Another way to obtain progression information is based
on changes in chemotherapy drugs in a patient, but this
method can only give imprecise assumptions on progres-
sion. Many patients with earlier stage colorectal cancer will
develop metastatic disease due to progression after their
initial treatments. Because of not being able to capture
cancer progression data electronically, we presently cannot
identify these patients or include them in the outcome
evaluation. In addition, data from the EMR is patient
specific but not cancer specific; therefore, the linkage
between the Cancer Registry and the EMR is not a
straightforward process for patients who had more than
one primary cancer. Improvements in linkage techniques or
Fig. 1 Median overall survival
(OS) from the first
chemotheraphy




























Number of patients: 168
+: Censored by the end of September 2006
or death due to other reason
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in the linkage of treatment information to specific cancers
could improve the quality of the linked data.
In the current study, using data from the EMR, the
median OS was 17.5 months for a cohort of patients who
were diagnosed in 2004 and received chemotherapy in
Alberta. This was quite close to the 18 months achieved in
clinical trials. However, because of selection bias, survival
results from our observational cohort cannot be compared
directly with that from the randomized clinical trials. Most
of the published evidence on the efficacy of a treatment is
based on well-controlled randomized clinical trials that are
usually conducted among selected patients. Specific selec-
tion criteria are used to ensure that treatment and control
groups are similar in relation to the distribution of factors
influencing the treatment outcomes [20]. Patients over
70 years of age are often under-represented in these
treatment trials [21]. In contrast, our study included patients
in real clinical care environments, and nearly half of them
were older than 70; many of them might have important co-
morbidities. Median OS of these patients seen in clinical
practice may have been worse than that for the patients
selected for clinical trials. Nevertheless, this study has
demonstrated the applicability of randomized clinical trial data
in the evaluation of treatment outcomes in clinical practice.
The focus of this population-based study was to
investigate the survival for patients who were given
chemotherapy in a representative patient population in
Alberta. This study has demonstrated an opportunity to
conduct ongoing evaluation and monitoring of outcomes
using a population-based data set established by linking the
Cancer Registry data with an EMR clinical database. The
results from these ongoing evaluations can contribute to
clinical decision making and to policy development [22].
The priorities in developing this ongoing system include
accurately linking Cancer Registry data and the data from
the EMR by patient and diagnosis, capturing cancer
recurrence and cancer progression information, identifying
key outcome indicators and associated data elements that
are routinely collected in the EMR, and improving the
quality of the key data elements used in the treatment
outcome evaluation.
Chemotherapy given to patients who had diagnosed with
metastatic cancer or had recurrent cancer is palliative
chemotherapy. When considering the treatment and care
for patients whose cancers have developed to an advanced
stage, the type of supportive care and the quality of life of
the patients are as important as survival improvement.
Conclusions
There was an improvement in the survival of metastatic
colorectal cancer patients in recent years in Alberta and this
improvement is most likely attributable in large part to the
chemotherapy treatment that they received.
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